Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 10/20 | 0.46 |
| ▸ | PTGER3 | P43115 | 7/20 | 0.46 |
| ▸ | PTGER2 | P43116 | 6/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9150751 | 0.84 | ALDH1A1 (0.50) | PTGER4PTGER3PTGER2MEN1KMT2A | |
| SCHEMBL13331904 | 0.82 | ALDH1A1 (0.48) | PTGER4PTGER3PTGER2MEN1KMT2A | |
| SCHEMBL242586 | 0.80 | MEN1 (0.51) | PTGER4PTGER3PTGER2MEN1KMT2A | |
| SCHEMBL8761610 | 0.80 | MEN1 (0.51) | PTGER4PTGER3PTGER2MEN1KMT2A | |
| SCHEMBL8748944 | 0.80 | MEN1 (0.51) | PTGER4PTGER3PTGER2MEN1KMT2A | |
| SCHEMBL8749215 | 0.80 | MEN1 (0.51) | PTGER4PTGER3PTGER2MEN1KMT2A | |
| SCHEMBL8761736 | 0.80 | MEN1 (0.51) | PTGER4PTGER3PTGER2MEN1KMT2A | |
| SCHEMBL8754825 | 0.80 | MEN1 (0.51) | PTGER4PTGER3PTGER2MEN1KMT2A | |
| SCHEMBL3425106 | 0.80 | MEN1 (0.51) | PTGER4PTGER3PTGER2MEN1KMT2A | |
| SCHEMBL8748862 | 0.80 | MEN1 (0.51) | PTGER4PTGER3PTGER2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1980237-B1 | GELLING AGENT | AJINOMOTO KK (JP) | 2013-10-02 | — | — | EP | disclosed |
| US-7850955-B2 | contain a specific N-acylamino acid monoamide monoalkyl ester; do not cause sweating while retaining a practical level of gel strength; good spreadability, and good fittability to skin; antiperspirants | AJINOMOTO CO., INC. (JP) | 2010-12-14 | — | — | US | disclosed |
| US-20080311164-A1 | GELLING AGENT | AJINOMOTO CO. INC (JP) | 2008-12-18 | — | — | US | disclosed |
| EP-1980237-A1 | GELLING AGENT | Ajinomoto Co., Inc. (JP) | 2008-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311164-A1 | GELLING AGENT | CUTA, NAAA, ASIC1 | PTGER4 934/4885PTGER3 1057/4885PTGER2 966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.